Cichoz-Lach H, Daniluk J, Słomka M, Celiński K, Pokora J
Katedry i Kliniki Gastroenterologii AM, Lublinie.
Pol Arch Med Wewn. 1992 Oct;88(4):250-5.
This paper presents results of 3-18 year clinical observation of 48 patients with chronic active hepatitis HBsAg (+). 40 patients had suffered viral hepatitis for a period from 6 months to 3 years (avg. 1.5 year) before chronic active hepatitis manifested. Cirrhosis hepatis was a consequence of chronic active hepatitis in 52.1%, chronic active hepatitis in 45.8%, and chronic persistence in 2.1% of cases, during observation period. The average transition time from chronic active hepatitis to cirrhosis was 3 years. 48% of cirrhosis hepatis occurred within 2 years starting from recognition of chronic active hepatitis and 80% within 5 years. Most cases of cirrhosis were recorded if patients had been treated with penicillamine and prednisone (80% of cases), then with azathioprine and prednisone (48% of cases), while the least with ++non-immunosuppressive therapy (penicillamine, isoprinosine or "+hepatic protectors").
本文介绍了对48例慢性活动性乙肝表面抗原(HBsAg)阳性患者进行3至18年临床观察的结果。40例患者在慢性活动性肝炎出现之前,患病毒性肝炎的时间为6个月至3年(平均1.5年)。在观察期内,52.1%的病例中肝硬化是慢性活动性肝炎的后果,45.8%为慢性活动性肝炎,2.1%为慢性迁延性肝炎。从慢性活动性肝炎转变为肝硬化的平均时间为3年。48%的肝硬化发生在确诊慢性活动性肝炎后的2年内,80%发生在5年内。如果患者接受青霉胺和泼尼松治疗(80%的病例),然后接受硫唑嘌呤和泼尼松治疗(48%的病例),则记录到的肝硬化病例最多,而接受非免疫抑制治疗(青霉胺、异丙肌苷或“肝脏保护剂”)的病例最少。